

## Special Issue

# Cancer Immunotherapy and Vaccines Research

### Message from the Guest Editors

Dear colleagues, Cancer vaccines are one of the main pillars of the cancer immunotherapy even in the era of checkpoint inhibitors. Indeed, although the latter have completely changed the scenario of cancer treatment, several patients do not benefit from them. However, the cancer vaccine field is still a work in progress field because an effective strategy has not been developed yet. The topic of the special issue will cover all the aspects involved in the vaccine research and development (i.e. identification of optimal target antigens, formulations, delivery strategies, adjuvants, combination with other immunomodulatory approaches).

---

### Guest Editors

Dr. Luigi Buonaguro

Innovative Immunological Models Unit, National Cancer Institute - IRCCS "Pascale", Via Mariano, Semmola, 52, 80131 Napoli, Italy

Dr. Maria Tagliamonte

Laboratory of Innovative Immunological Models, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy

---

### Deadline for manuscript submissions

closed (28 February 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/63453](https://mdpi.com/si/63453)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).